NCT07123350View on ClinicalTrials.gov

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Active, not recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Inflammatory Bowel Disease (IBD)Crohn&Amp;#39;s Disease (CD)Ulcerative Colitis (UC)
Interventions
DRUG

Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care

This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.

Trial Locations (1)

37211

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Takeda Pharmaceuticals U.S.A., Inc.

UNKNOWN

lead

Vanderbilt University Medical Center

OTHER